http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013154741-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7052 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-23 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7064 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-167 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2012-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-07-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013154741-A |
| titleOfInvention | NEW TICAGRELOR CO-CRYSTAL |
| abstract | 1. Co-crystal of the compound {1S- [1α, 2α, 3β (1S *, 2R *), 5β]} - 3- (7 - {[2- (3,4-difluorophenyl) cyclopropyl] amino} -5- (propylthio ) -3H-1,2,3-triazolo [4,5-d] pyrimidin-3-yl) -5- (2-hydroxyethoxy) cyclopentan-1,2-diol of formula (I) and a co-crystal forming molecule, where The cocrystal-forming molecule is acetylsalicylic acid. 2. A co-crystal of the compound of formula (I) and acetylsalicylic acid according to claim 1, characterized in that it has a powder X-ray diffraction pattern with the peaks indicated in the Table below where 2-theta values are +/- 0.2 ° .3 . A co-crystal of the compound of formula (I) and acetylsalicylic acid according to claim 2, characterized in that it has an X-ray powder diffraction pattern with peaks, in addition to the peaks indicated in clause 2, which are indicated in the Table below where 2-theta values represent values +/- 0.2 °. 4. A co-crystal of the compound of formula (I) and acetylsalicylic acid according to any one of claims 1 to 3, characterized in that it has a stoichiometry of approximately 3: 2 Compound A: acetylsalicylic acid. 5. A method for producing a co-crystal of a compound of formula (I) and acetylsalicylic acid according to claim 1, comprising mixing a suspension of a compound of formula (I) and acetylsalicylic acid in a suitable solvent, such as dichloromethane. 6. A method for producing a cocrystal of a compound of formula (I) and acetylsalicylic acid according to claim 5, wherein polymorph III of the compound of formula (I) is used. A pharmaceutical composition comprising a cocrystal of a compound of formula (I) and acetylsalicylic acid according to any one of claims 1 to 4 and a pharmaceutically acceptable diluent or carrier. A co-crystal of the compound of formula (I) and acetylsalicylic acid as desired |
| priorityDate | 2011-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.